Please also see discussions about PCYC under QLT area.
Pharmacyclics is a company with three products in clinical development
and multiple compounds in preclinical development. Their products are:
Gd-Tex (gadolinium texophyrin), a radiation sensitizer. This product
is in Phase I trials, which are still open for enrollment. They are
studying effects on brain metastases, as well as looking at MDT's
(maximum tolerable dose).
Lu-Tex (lutetium texaphyrin PCI-0123), a light activated drug being
studied for treatment of various cutaneous tumors, including Kaposis
Sarcoma, melanoma, breast CA, and others. It is in Phase I trials,
the interim results of which looked very favorable for both efficacy
and toxicity. In fact, it could be a very important compound when and
if they demonstrate its efficacy in trials, because the drug has a fairly
short half-life, which limits its toxicity.
Gadolite oral suspension, an MRI contrast agent for the GI tract. This
is in Phase III trials and a NDA has been filed.
I believe they will compete in a difficult but very promising market.
The real question will be what , if any, advantages will Lu-Tex
have over products being studied by QLT and PDT. The CEO of PCYC is
Rich Miller who founded IDEC pharmaceuticals and he is supposedly
a very bright guy and whatever he touches seems to work (both
scientifically and for the shareholders).
I am not a stock promoter nor am I a principal of the company,
but I have been watching PCYC for several months and just
bought some shares due to the recent weakness in its stock price, and
because of the potential for its products.
I would love to keep and ongoing discussion about this company.
Doug |
